Q-omics provides the consensus-scored HOXD4 profile across patient tissues and cancer cell-line models. HOXD4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HOXD4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, HOXD4 RNA expression shows 14,491 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where HOXD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXD4 survival associations across molecular data types. HOXD4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXD4 RNA expression–survival associations across cancer types. High HOXD4 expression shows unfavorable associations in UCEC, KIRP, ACC, LGG, COAD and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for HOXD4 RNA expression.
This table summarizes HOXD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HOXD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXD4 shows lower tumor expression in KIRC, COAD, KICH and UCEC and higher tumor expression in LIHC and BLCA. The KIRC box plot shows higher HOXD4 RNA expression in normal versus tumor tissue (log2 FC = −1.159, t-test p < 0.001).
This table shows molecular features associated with HOXD4 in patient tissues and cancer cell lines. In patient samples, HOXD4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
